Cellectis stock tumbles after Barclays double downgrade
Cellectis SA (CLLS) shares dropped 14.6% after Barclays downgraded the stock to Underweight, cutting its price target to $1.30 from $9.00. Analyst Lukas Shumway cited lack of conviction in Cellectis' new programs, assigning negative net present values to .HEAL-101 and .HEAL-201. The valuation model now includes $2 each for Royalties and Milestones, -$1 for Debt, and $5 for Cash, assuming a capital raise in late 2027.
How this was made
The 30-second read
Why it matters
The downgrade sharply reduces valuation expectations, likely prompting sell orders.
Market read
The downgrade drives a notable price move and may affect sentiment in the biotech sector.
What to watch
Potential upcoming clinical data for .HEAL‑101 could mitigate downside if positive.
Background
Cellectis is a gene‑editing company listed on NASDAQ; recent analyst coverage has been mixed.
Ticker impact
Barclays downgraded CLLS to Underweight and cut the price target to $1.30, triggering a 14.6% share drop.
Further short-term decline as investors reassess valuation.
Analyst removed valuation for key programs and lowered cash assumptions, indicating weak outlook.
Market effects
Negative sentiment may spill to other gene‑editing and biotech stocks.
Limited to US biotech sector.
Minimal global impact beyond niche biotech investors.
Counterpoint
If the downgrade overstates risks, the stock could rebound on short‑covering.
Key entities
- AnalystBarclays
Issued the downgrade and target cut.
